Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

stallergenes greer new zealand ltd - grass pollen extract 100 ir; allergen extracts 300 ir (grass pollen) - sublingual tablet - active: grass pollen extract 100 ir excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose active: allergen extracts 300 ir (grass pollen) excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

alk-abello a/s - grass pollen extract (phleum pratense) - sublingual lyophilisate - 75, 000 standardised quality units tablet - allergen extracts; grass pollen

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

stallergenes s.a. - grass pollen allergen extract - tablet sublingual - 100/300

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

stallergenes s.a. - grass pollen allergen extract - tablet sublingual - 300

Malta - angielski - Medicines Authority

stallergenes s.a. 6 rue alexis de tocqueville, 92160 antony, france - grass pollen, allergen extract - sublingual tablet - grass pollen allergen extract - allergens

Malta - angielski - Medicines Authority

stallergenes s.a. 6 rue alexis de tocqueville, 92160 antony, france - grass pollen, allergen extract - sublingual tablet - grass pollen allergen extract 300 ir - allergens

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

stallergenes - grass pollen allergen extract - sublingual tablet - 100/300 index of reactivity - allergen extracts; grass pollen

Irlandia - angielski - HPRA (Health Products Regulatory Authority)

stallergenes - grass pollen allergen extract - sublingual tablet - 300 index of reactivity - allergen extracts; grass pollen

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

stallergenes - phleum pratense pollen (unii: 65m88rw2eg) (phleum pratense top - unii:s7pw24bx20, phleum pratense pollen - unii:65m88rw2eg), anthoxanthum odoratum pollen (unii: 2kik19r45y) (anthoxanthum odoratum pollen - unii:2kik19r45y), dactylis glomerata pollen (unii: 83n78ida7p) (dactylis glomerata pollen - unii:83n78ida7p), poa pratensis pollen (unii: scb8j7ls3t) (poa pratensis pollen - unii:scb8j7ls3t), lolium perenne pollen (unii: 4t81lb52r0) (lolium perenne pollen - unii:4t81lb52r0) - anthoxanthum odoratum pollen 100 [ir] - oralair is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific ige antibodies for any of the five grass species contained in this product. oralair is approved for use in persons 5 through 65 years of age. oralair is not indicated for the immediate relief of allergy symptoms. oralair is contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic allergic reaction - history of any severe local reaction to sublingual allergen immunotherapy - a history of eosinophilic esophagitis - hypersensitivity to any of the inactive ingredients (mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate and lactose monohydrate) contained in this product [ see description (11) ] risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

stallergenes australia pty ltd - poa pratensis, quantity: 20 %; anthoxanthum odoratum, quantity: 20 %; phleum pratense, quantity: 20 %; dactylis glomerata, quantity: 20 %; lolium perenne, quantity: 20 % - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; lactose monohydrate - treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titre of the specific ige to the grass pollen.